This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Applied Genetic Technologies Past Earnings Performance
Past criteria checks 0/6
Key information
-39.8%
Earnings growth rate
-21.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -57.4% |
| Return on equity | -398.0% |
| Net Margin | -21,610.5% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
AGTC receives positive feedback from FDA for manufacturing facility
Jul 26Applied Genetic Technologies proposes stock offering to fund clinical trials
Jul 12Applied Genetic Tech: A Speculative Biotech With Potential To Turn Corner In 2022
Jan 12An Assessment Of Applied Genetic Technologies Corporation
Dec 14Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk
Jul 15Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?
May 21
Applied Genetic trades lower after announcing the departure of chief scientific officer
Apr 26What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?
Feb 05
Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?
Jan 06What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Dec 11Interim data on gene therapy for vision loss disorder fails to lift Applied Genetic
Nov 11Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow Applied Genetic Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -70 | 17 | 28 |
| 30 Jun 22 | 0 | -69 | 17 | 28 |
| 31 Mar 22 | 1 | -63 | 17 | 25 |
| 31 Dec 21 | 1 | -63 | 16 | 23 |
| 30 Sep 21 | 1 | -60 | 15 | 22 |
| 30 Jun 21 | 1 | -58 | 15 | 21 |
| 31 Mar 21 | 0 | -60 | 14 | 21 |
| 31 Dec 20 | 0 | -57 | 14 | 21 |
| 30 Sep 20 | 2 | -50 | 14 | 27 |
| 30 Jun 20 | 2 | -46 | 14 | 21 |
| 31 Mar 20 | 3 | -42 | 13 | 21 |
| 31 Dec 19 | 24 | -19 | 13 | 29 |
| 30 Sep 19 | 28 | -15 | 13 | 20 |
| 30 Jun 19 | 42 | -2 | 13 | 19 |
| 31 Mar 19 | 47 | 2 | 13 | 2 |
| 31 Dec 18 | 29 | -18 | 14 | 1 |
| 30 Sep 18 | 28 | -19 | 14 | 5 |
| 30 Jun 18 | 24 | -21 | 14 | 0 |
| 31 Mar 18 | 27 | -18 | 14 | 27 |
| 31 Dec 17 | 32 | -11 | 13 | 15 |
| 30 Sep 17 | 38 | -4 | 12 | 15 |
| 30 Jun 17 | 39 | 0 | 11 | 15 |
| 31 Mar 17 | 43 | 6 | 11 | 11 |
| 31 Dec 16 | 47 | 10 | 10 | 11 |
| 30 Sep 16 | 48 | 11 | 10 | 11 |
| 30 Jun 16 | 47 | -1 | 10 | 11 |
| 31 Mar 16 | 36 | -12 | 10 | 0 |
| 31 Dec 15 | 24 | -20 | 11 | 0 |
Quality Earnings: AGTC is currently unprofitable.
Growing Profit Margin: AGTC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AGTC is unprofitable, and losses have increased over the past 5 years at a rate of 39.8% per year.
Accelerating Growth: Unable to compare AGTC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AGTC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (60.8%).
Return on Equity
High ROE: AGTC has a negative Return on Equity (-398.02%), as it is currently unprofitable.